← Eichor
Study identifier: NCT07734584 Synced from ClinicalTrials.gov · July 29, 2026
● Recruiting

A Standard Carbon Dioxide Flushing Protocol to Reduce Air Embolization During Thoracic Endovascular Aortic Repair

Condition: Type B Acute Aortic Syndrome · Thoracic and Thoracoabdominal Aneurysms With Crawford Extent I, II, III, or IV  ·  Sponsor: University of Bologna

PhaseNA
Planned participants90
Who can joinAll sexes, 18 Years to no upper limit
Healthy volunteersNo

About this study

FlushTEVAR is a non-profit, interventional, randomized, controlled, single-blind, national multicenter study promoted by the University of Bologna and coordinated by the Vascular Surgery Unit of IRCCS Azienda Ospedaliero-Universitaria di Bologna, Policlinico di Sant'Orsola, under the direction of Prof. Mauro Gargiulo, who also serves as Principal Investigator. The study aims to develop and evaluate a pre-implant thoracic endograft flushing technique using carbon dioxide (CO₂) to reduce periprocedural embolic events and cerebral infarctions in patients undergoing Thoracic Endovascular Aortic Repair (TEVAR). TEVAR is currently the treatment of choice for acute aortic syndromes and aneurysms involving the descending thoracic aorta. Despite its widespread use, TEVAR remains associated with significant neurological complications, with an incidence ranging from 3% to 8% in standard procedures and reaching up to 16% in more complex endovascular interventions. Cerebral embolization caused by solid and gaseous particles is considered the main cause of perioperative stroke and silent brain infarction (SBI), the latter being defined as ischemic brain injury detected by neuroradiological imaging in the absence of immediate clinical symptoms. During TEVAR, approximately 90% of microembolic signals detected in the middle cerebral artery are caused by gaseous emboli, with the highest number occurring during endograft deployment. This phenomenon is associated with the manufacturing and ster…

This description comes directly from the study's public registry record.

Talk to the study team

Mauro Gargiulo, MD  ·  0512144252  ·  mauro.gargiulo2@unibo.it

Chiara Mascoli, MD  ·  0512144278  ·  chiara.mascoli@aosp.bo.it

Always discuss trial participation with your own doctor first.

Locations (4)

IRCCS Azienda Ospedaliero-Universitaria di BolognaBologna, Italy, ItalyRecruiting
A.S.S.T. Spedali Civili di BresciaBrescia, Italy, ItalyNot Yet Recruiting
IRCCS Policlinico San Martino di GenovaGenova, Italy, ItalyNot Yet Recruiting
Azienda Ospedaliero-Universitaria di PadovaPadova, Italy, ItalyNot Yet Recruiting

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.

Source record: clinicaltrials.gov/study/NCT07734584